Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant.
Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant.
复制标题
DOI：
10.1038/s41598-021-01363-7
复制
发表时间：
2021-11-08
影响因子：
4.6
通讯作者：
McCluskie MJ
中科院分区：
文献类型：
--
作者：
Akache B;Renner TM;Tran A;Deschatelets L;Dudani R;Harrison BA;Duque D;Haukenfrers J;Rossotti MA;Gaudreault F;Hemraz UD;Lam E;Régnier S;Chen W;Gervais C;Stuible M;Krishnan L;Durocher Y;McCluskie MJ
全球对针对SARS-CoV-2的疫苗的巨大需求使得继续开发能够减轻新冠肺炎大流行负担的新型改进配方是必要的。在此，我们评估了含有抵抗素三聚化尖峰抗原SmT1的新型蛋白质亚单位疫苗配方。当与硫酸乳糖基考古醇(SLA)考古体佐剂结合时，制剂可在小鼠中诱导强大的抗原特异性体液和细胞免疫反应。抗体具有很强的中和活性，可防止病毒尖峰结合和病毒感染。此外，这些配方在仓鼠挑战模型中非常有效，即使在单一疫苗接种后也能减少病毒载量和体重减轻。我们的疫苗配方产生的抗原特异性抗体比人类恢复期血浆具有更强的中和活性，中和了令人担忧的B.1.1.7和B.1.351变种的刺突蛋白。因此，我们的SmT1抗原和SLA古体佐剂一起构成了一个有希望的平台，用于开发有效的SARS-CoV-2蛋白亚单位疫苗配方。
The huge worldwide demand for vaccines targeting SARS-CoV-2 has necessitated the continued development of novel improved formulations capable of reducing the burden of the COVID-19 pandemic. Herein, we evaluated novel protein subunit vaccine formulations containing a resistin-trimerized spike antigen, SmT1. When combined with sulfated lactosyl archaeol (SLA) archaeosome adjuvant, formulations induced robust antigen-specific humoral and cellular immune responses in mice. Antibodies had strong neutralizing activity, preventing viral spike binding and viral infection. In addition, the formulations were highly efficacious in a hamster challenge model reducing viral load and body weight loss even after a single vaccination. The antigen-specific antibodies generated by our vaccine formulations had stronger neutralizing activity than human convalescent plasma, neutralizing the spike proteins of the B.1.1.7 and B.1.351 variants of concern. As such, our SmT1 antigen along with SLA archaeosome adjuvant comprise a promising platform for the development of efficacious protein subunit vaccine formulations for SARS-CoV-2.
登录
查看更多内容
影响因子：
5.5
作者：
Hatziantoniou S;Maltezou HC;Tsakris A;Poland GA;Anastassopoulou C
通讯作者：
Anastassopoulou C
DOI：
10.1056/nejmoa2104840
发表时间：
2021-06-03
期刊：
The New England journal of medicine
影响因子：
--
作者：
Greinacher A;Thiele T;Warkentin TE;Weisser K;Kyrle PA;Eichinger S
通讯作者：
Eichinger S
影响因子：
8
作者：
Abe, Kento T.;Li, Zhijie;Gingras, Anne-Claude
通讯作者：
Gingras, Anne-Claude
影响因子：
158.5
作者：
Keech, Cheryl;Albert, Gary;Glenn, Gregory M.
通讯作者：
Glenn, Gregory M.
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group